Search results for " Middle"

showing 10 items of 1097 documents

Bioactive Glass-Ceramics in Middle Ear Surgery An 8-Year Review

1988

An 8-year follow-up of Ceravital middle ear prostheses showed there was extremely good tolerance in the middle ear space. Incompatibility phenomena were not observed, and inflammatory reactions were neither caused nor supported by the implants. The tympanoplasties were always performed without interposition of cartilage between the tympanic membrane or the tympanic membrane graft and the disk-shaped portion of the implant, and extrusions were never observed. Long-lasting inflammatory processes appeared to destroy implants the same way they destroy ossicles. Transient inflammatory periods (such as episodes of purulent otitis media, which occurred soon after the prostheses were implanted) did…

CeramicsTympanic MembraneChemical PhenomenaEar MiddleDentistryBiocompatible MaterialsProsthesis DesignEpitheliumGeneral Biochemistry Genetics and Molecular Biologylaw.inventionHistory and Philosophy of SciencelawmedicineHumansOssiclesChemistry Physicalbusiness.industryGeneral NeuroscienceCartilageOssicular Prosthesismedicine.anatomical_structureHearing resultsMiddle ear surgeryBioactive glassMiddle earImplantPurulent Otitis MediabusinessEar CanalAnnals of the New York Academy of Sciences
researchProduct

Tissue reactions to glass ceramics in the middle ear

1981

The bioactive glass ceramic "Ceravital" was used to fashion prostheses for the replacement of various ossicles in the middle ear. They were tested in 70 rabbit ears, where they were accepted in osseous areas without formation of surrounding fibrous tissue. Histological examinations regularly showed an osseous bond with the surrounding bony tissue. Mucous membrane covered these ossicular chain prostheses and showed no evidence of inflammatory reactions. Glass ceramic implants were also used to reconstruct the ossicular chain and the posterior wall of the outer ear canal in 100 patients. The functional results were satisfactory in all cases.

Ceramicsmedicine.medical_treatmentEar MiddleDentistrylaw.inventionTympanoplastylawotorhinolaryngologic diseasesmedicineOuter earAnimalsCeramicOssicular chainOssiclesbusiness.industryMucous membraneProstheses and ImplantsAnatomyTympanoplastymedicine.anatomical_structureOtorhinolaryngologyBioactive glassvisual_artvisual_art.visual_art_mediumMiddle earRabbitssense organsbusinessClinical Otolaryngology
researchProduct

Le fistole liquorali nella patologia otologica

2005

Cerebrospinal fluid fistulas in the otologic pathology show the presence of one or more anomalous touches between subaracnoids spaces and temporal bone. Cerebrospinal fluid fistulas are distinguished in congenital and acquired. The acquired fistulas are the most large group and they include post-traumatic fistulas, post-infective fistulas and/or post-inflammatory fistulas, iatrogenic fistulas, post-neoplastic fistulas and spontaneous fistulas. The congenital fistulas are more rare, they involve otic capsula and are, often, associated with malformations of inner ear. The critical analysis of our data leads, in our opinion, to some interesting diagnostic considerations. © Copyright 2005, CIC …

Cerebrospinal fluid fistulas Pathology of middle ear
researchProduct

Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical canc…

2015

Objective: To investigate the feasibility and determine the recommended pre-operative intensity-modulated radiotherapy (IMRT) dose of extended-field chemoradiation along with simultaneous integrated boost (SIB) dose escalation. Methods: A radiation dose of 40Gy over 4 weeks, 2Gy/fraction, was delivered to the tumour and the lymphatic drainage (planning target volume, PTV3), which encompassed a volume larger than standard (common iliac lymphatic area up to its apex, in front of the L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil). Radiation dose was escalated to the pelvis (PTV2) and to the macroscopic disease (PTV1) with the SIB-IMRT strategy. Three dose levels we…

Chemoradiotherapy; Dose Fractionation; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Preoperative Period; Prospective Studies; Radiotherapy Dosage; Radiotherapy Planning Computer-Assisted; Radiotherapy Intensity-Modulated; Treatment Outcome; Uterine Cervical Neoplasms; Radiology Nuclear Medicine and Imaging; Medicine (all)Uterine Cervical NeoplasmRadiology Nuclear Medicine and Imagingcervical cancermedicine.medical_treatmentUterine Cervical NeoplasmsMedicineHumansProspective StudiesProspective cohort studyDose FractionationSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIANeoplasm StagingCervical cancerCisplatinChemotherapyFull Paperbusiness.industryMedicine (all)Radiotherapy Planning Computer-AssistedDose fractionationRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle Agedmedicine.diseaseRadiation therapyFeasibility StudieProspective StudieLymphatic systemTreatment OutcomePreoperative PeriodFeasibility StudiesFemaleDose Fractionation RadiationRadiotherapy Intensity-ModulatedbusinessNuclear medicineChemoradiotherapymedicine.drugHumanThe British journal of radiology
researchProduct

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

2014

Abstract Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the …

Chemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sulfonamides; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2; Cancer Research; Oncology; Medicine (all)OncologyMaleCancer ResearchIndolesAxitinibPyridinesPyridinemedicine.medical_treatmentSolitary fibrous tumourAdministration OralAngiogenesis InhibitorsMice SCIDPharmacologyPyrroleAntineoplastic Agentchemistry.chemical_compoundMiceSolitary Fibrous TumorChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Cancer Research; Oncology; Medicine (all)Transplantation HeterologouMonoclonalSunitinibHumanizedSulfonamidesHeterologousSunitinibMedicine (all)ImidazolesSarcomaMiddle AgedSorafenibPlatelet-Derived Growth Factor betaAxitinibBevacizumabOncologySolitary Fibrous TumorsAdministrationAngiogenesis InhibitorHumanmedicine.drugReceptorPhenylurea CompoundSorafenibOralAdultNiacinamidemedicine.medical_specialtyIndazolesBevacizumabMAP Kinase Signaling SystemTransplantation HeterologousAntineoplastic AgentsSulfonamideAntibodies Monoclonal HumanizedSCIDAntibodiesReceptor Platelet-Derived Growth Factor betaPazopanibInternal medicineRegorafenibmedicineAnimalsHumansChemotherapyPyrrolesImidazoleTyrosine kinaseAgedChemotherapyTransplantationAnimalbusiness.industryPhenylurea CompoundsPazopanibmedicine.diseaseChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2IndazolePyrimidinesPyrimidinechemistryIndolebusinessProgressive diseaseNeoplasm Transplantation
researchProduct

Is loneliness associated with mild cognitive impairment in low- and middle-income countries?

2021

Background: Loneliness may be a risk factor for mild cognitive impairment but studies on this topic are scarce, particularly from low- and middle-income countries (LMICs). Therefore, the aim of the present study was to investigate the association between loneliness and mild cognitive impairment (MCI) in six LMICs (China, Ghana, India, Mexico, Russia and South Africa). Methods: Cross-sectional, community-based, nationally representative data from the WHO Study on global AGEing and adult health (SAGE) were analyzed. The definition of MCI was based on the National Institute on Ageing-Alzheimer's Association criteria. Multivariable logistic regression analysis and meta-analysis were conducted t…

ChinaLogistic regression*multi-countryOdds*loneliness03 medical and health sciences0302 clinical medicinemild cognitive impairmentMESH: Aged; China/epidemiology; Cognitive Dysfunction/epidemiology; Cross-Sectional Studies; Developing Countries; Humans; Loneliness; Middle Aged; PrevalencemedicinePrevalencelonelinessDementiaHumansCognitive Dysfunctionlow- and middle-income countriesRisk factorCognitive impairmentDeveloping CountriesAgedmulti-country030214 geriatricsbusiness.industryLonelinessMiddle Agedmedicine.disease*low- and middle-income countriesConfidence interval3. Good healthPsychiatry and Mental healthCross-Sectional Studies*mild cognitive impairmentLow and middle income countriesloneliness low- and middle-income countries mild cognitive impairment multi-country[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieGeriatrics and Gerontologymedicine.symptombusinessDemography
researchProduct

Le città nuove della Sicilia Occidentale nel Trecento tra Corona e baronaggio

2013

Nella Sicilia del Trecento Federico III incoraggia la creazione di nuovi centri urbani in luoghi difficilmente espugnabili. Le fondazioni delle famiglie nobiliari emergenti si rivelano più durature e riflettono il loro peso politico-territoriale. Basti ricordare Castelbuono, centro dei Ventimiglia nelle Madonie; Chiusa, opera del conte Matteo Sclafani; Mussomeli Favara e Siculiana erette dai Chiaromonte per estendere il controllo territoriale a sud di Palermo.

Cities Sicily Middle AgesSettore M-STO/01 - Storia MedievaleCittà Sicilia Medioevo
researchProduct

A Companion to Medieval Palermo

2015

The aim of this book is to recast the medieval history of Palermo beyond the old and stereotypical idea of a city characterised by political immaturity and cultural richness due to a series of fore...

Cities. Sicily. Middle Ages.Città. Sicilia. Medioevo.Medieval historyHistoryPoliticsHistoryReligious studiesSettore M-STO/01 - Storia MedievaleAncient historyAl-Masāq
researchProduct

Favara

2013

Nella Descriptio feudorum del 1335 Giovanni Chiaromonte il Vecchio è proprietario di Favara. Nel 1375 il casale ha 51 fuochi e appartiene all’ammiraglio Manfredi Chiaromonte. Il centro urbano medievale di Favara si struttura e si espande grazie al privilegio di affidare, che favorisce il popolamento, poiché garantisce il condono delle pene ai delinquenti e ai debitori insolventi che si trasferiscono nel casale.

Cities. Sicily. Middle Ages.Settore M-STO/01 - Storia MedievaleCittà Sicilia Medioevo
researchProduct

Chiusa Sclafani

2013

Matteo Sclafani, conte di Adrano, ebbe dalla prima moglie, Bartolomea Incisa il casale di Chiusa, che popolò e dotò di un castello. Nel testamento del 1354 Matteo lasciò Chiusa al nipote Guglielmone Peralta, nato dalla figlia Aloisa e da Guglielmo Peralta. Morto Nicolò Peralta divennero signori di Chiusa i figli Gabriele e Caterina, avuti da Isabella Luna.

Cities. Sicily. Middle Ages.Settore M-STO/01 - Storia MedievaleCittà Sicilia Medioevo
researchProduct